Skip to main content
Erschienen in: Clinical and Translational Oncology 3/2020

09.05.2019 | Correspondence

De-escalation treatment of axilla in breast cancer

verfasst von: G. Corso, V. Galimberti, P. Veronesi

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Excerpt

In cases of negative axillary staging, axillary lymph node dissection (ALND) has been replaced by sentinel node (SN) biopsy as the standard treatment for BC. ALND following a positive SN biopsy is being progressively abandoned. Results from the latest 10 years, phase 3 trial (IBCSG 23-01) confirmed that if the SN displays only micrometastases, then ALND is not indicated [1]. However, ALND is routinely performed in cases of macrometastatic SN biopsy, in particular after mastectomy. In breast-conserving surgery (BCS), results from the ACOSOG Z0011 trial contraindicated ALND if only one to two SNs are positive. ALND is still recommended if ≥ 3 SNs contain metastases or macroscopic lymph node is found intraoperatively [2]. …
Literatur
Metadaten
Titel
De-escalation treatment of axilla in breast cancer
verfasst von
G. Corso
V. Galimberti
P. Veronesi
Publikationsdatum
09.05.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 3/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02129-4

Weitere Artikel der Ausgabe 3/2020

Clinical and Translational Oncology 3/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.